ResearcherUniversity of Alabama at BirminghamActive in the last 2 years
Utpreksha Vaish
Matched on ORCID iD 0000-0002-8370-442X; OpenAlex author ID A5065871484. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2021: 3 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC. Co-author DOI 10.1016/j.cytogfr.2026.01.009↗
- Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancrea… Co-author DOI 10.1007/s00535-025-02213-3↗
- Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
- Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Co-author DOI 10.1080/2162402x.2021.1976952↗
- Modulation of Early Neutrophil Granulation: The Circulating Tumor Cell-Extravesicular Connection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112727↗
- Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Co-author DOI 10.3390/ijms222413408↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vikas Dudeja · 5 shared papers, 2021–2025 · strength 0.85
- Paper Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate… DOI 10.1007/s00535-025-02213-3↗
- Paper Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. DOI 10.3390/ijms222413408↗
- Paper Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. DOI 10.1016/j.hpb.2022.05.003↗
- Tejeshwar Jain · 4 shared papers, 2021–2026 · strength 0.71
- Paper Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC. DOI 10.1016/j.cytogfr.2026.01.009↗
- Paper Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. DOI 10.3390/ijms222413408↗
- Paper Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. DOI 10.1016/j.hpb.2022.05.003↗
- Srikanth Iyer · 3 shared papers, 2021–2026 · strength 0.52
- Paper Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC. DOI 10.1016/j.cytogfr.2026.01.009↗
- Paper Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. DOI 10.1016/j.hpb.2022.05.003↗
- Paper Hsp70 modulates immune response in pancreatic cancer through dendritic cells. DOI 10.1080/2162402x.2021.1976952↗
- Marwa Muhammad Abu-Serie · 1 shared paper, 2025 · strength 0.30
- Suresh Sulekha Dhanisha · 1 shared paper, 2026 · strength 0.29
- Vrishketan Sethi · 2 shared papers, 2021–2022 · strength 0.23
- Bhuwan Giri · 2 shared papers, 2021–2022 · strength 0.23
- Prateek Sharma MD · 2 shared papers, 2021–2022 · strength 0.23
- Ashok Kumar Saluja · 2 shared papers, 2021 · strength 0.22
- John Bart Rose · 1 shared paper, 2022 · strength 0.13
- Sushanth Reddy · 1 shared paper, 2022 · strength 0.13
- Nipun B. Merchant · 1 shared paper, 2022 · strength 0.13
- Suresh T. Chari · 1 shared paper, 2022 · strength 0.13
- Jashodeep Datta · 1 shared paper, 2022 · strength 0.13
- Harrys Charles Jacob · 1 shared paper, 2021 · strength 0.12
- Ashley Nicole Middleton · 1 shared paper, 2021 · strength 0.12
- Shweta Lavania · 1 shared paper, 2021 · strength 0.12
- Zoe X. Malchiodi · 1 shared paper, 2021 · strength 0.10
- Sundaram Ramakrishnan · 1 shared paper, 2021 · strength 0.10
- Bharti Garg · 1 shared paper, 2021 · strength 0.10
- Siddharth Mehra · 1 shared paper, 2021 · strength 0.10
- Harrys K.C. Jacob · 1 shared paper, 2021 · strength 0.10
- Anthony R. Ferrantella · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.